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Introduction {#acn350985-sec-0005}
============

Dynactin 1 (DCTN1), the largest subunit of the dynactin complex, interacts with microtubule and tubulin dimer, plays a protective role in stabilizing neuron cytoskeleton, and initiates dynein‐mediated axonal retrograde transport.[1](#acn350985-bib-0001){ref-type="ref"}, [2](#acn350985-bib-0002){ref-type="ref"} *DCTN1*‐related axonal deficiency leading to inherited motor neuron degeneration, ranges widely from distal hereditary motor neuronopathy (dHMN), Perry syndrome to amyotrophic lateral sclerosis (ALS).[3](#acn350985-bib-0003){ref-type="ref"}, [4](#acn350985-bib-0004){ref-type="ref"}, [5](#acn350985-bib-0005){ref-type="ref"} Different phenotypes are mainly characterized as involvement of inferior motor neurons or superior motor neurons or both, with different ages of onset and various progress speed. *DCTN1*‐related dHMN, also known as dHNM type 7B, presents with distal limb dystrophy and weakness appearing at early adulthood,[6](#acn350985-bib-0006){ref-type="ref"} whereas Perry syndrome is characterized by middle‐age‐onset parkinsonism, depression, weight loss, and central hypoventilation.[4](#acn350985-bib-0004){ref-type="ref"}, [7](#acn350985-bib-0007){ref-type="ref"}, [8](#acn350985-bib-0008){ref-type="ref"} Recently, frontotemporal dementia (FTD) has also been considered as one of the phenotypes,[9](#acn350985-bib-0009){ref-type="ref"} indicating the *DCTN1*‐related spectrum is still expanding. Since the year of 2003, *DCTN1* mutation was first associated with human disease,[6](#acn350985-bib-0006){ref-type="ref"} more than 20 variations have been reported in sporadic or familial cases.[4](#acn350985-bib-0004){ref-type="ref"}, [5](#acn350985-bib-0005){ref-type="ref"} However, rare of the *DCTN1* mutations have been functionally examined and the pathogenesis remains elusive.

Here we identified two patients due to different novel *DCTN1* mutations, manifesting as very early‐onset dHMN plus congenital foot deformity and ALS, respectively. On the basis of thorough clinical, pathological, and genetic analysis, we aimed to functionally investigate the pathogenesis of *DCNT1*‐related spectrum.

Materials and Methods {#acn350985-sec-0006}
=====================

Participants {#acn350985-sec-0007}
------------

We identified two patients fulfilling the diagnosis of motor neuron disease according to distal muscle atrophy and weakness as well as electrophysiological evidence.[10](#acn350985-bib-0010){ref-type="ref"}, [11](#acn350985-bib-0011){ref-type="ref"} Two patients and their parents were clinically examined.

Standard protocol approvals, registrations, and patient consents {#acn350985-sec-0008}
----------------------------------------------------------------

The ethics committee of Rui Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine approved the study. All participants provided written informed consent.

Mutation analysis {#acn350985-sec-0009}
-----------------

Genomic DNA was extracted using a standard phenol/chloroform extraction protocol. Healthy individuals (*n* = 300) of matched geographic ancestry were included as normal controls. Exome sequencing was performed for the patients, using Agilent SureSelect v6 reagents for capturing exons and Illumina HiSeq X Ten platform. Alignment to human genome assembly hg19 (GRCh37) was carried out followed by recalibration and variant calling. Population allele frequencies compiled from public databases of normal human variation (dbSNP, ESP6500, and 1000 g) were used to initially filter the data to exclude variants at greater than 1‰ frequency in the population. The variants were further interpreted and classified according to the American College of Medical Genetics and Genomics (ACMG) Standards and Guidelines.[12](#acn350985-bib-0012){ref-type="ref"} In this segment, two neurogeneticists analyzed the inheritance pattern, allele frequency (from: 1000 g, ESP6500, dbSNP, ExAC, and 300 in‐house ethnically matched healthy controls), amino acid conservation, pathogenicity prediction \[Mutationtaster (<http://www.mutationtaster.org>)\]. Putative pathogenic variants were further confirmed by Sanger sequencing both forward and reverse strands.

Neuropathology {#acn350985-sec-0010}
--------------

We performed open biopsy on the left sural nerve in Patient 1. The peripheral nerve tissue was frozen and then cut at 7 μm sections. These sections were stained according to standard histological and histochemical procedures with hematoxylin and eosin (HE), modified Gomori Trichrome (MGT), and Congo Red.

Electron micrograph {#acn350985-sec-0011}
-------------------

Fresh nerve tissue was postfixed in 2% PFA/2.5% glutaraldehyde in phosphate buffer, pH 7.2 overnight at 4°C. After PBS buffer rinse, samples were postfixed in 1% osmium tetroxide buffer (2 h) on ice in the dark. After a double‐distilled water rinse, tissue was stained with 3% aqueous uranyl acetate (0.22‐μm filtered; 1 h in the dark), dehydrated in a graded series of ethanol and propylene oxide, and embedded in Epoxy 618 resin. Samples were polymerized at 60°C for 48 h. Toluidine blue staining was performed on semithin sections (0.7--1.0 μm). Thin sections (60--90 nm) were cut with a diamond knife on the LKB V ultramicrotome and picked up with formvar‐coated copper slot grids. Grids were stained with lead citrate and observed with transmission microscopy (PHI LIP CM‐120).

Cell culture, transfection, and western blotting {#acn350985-sec-0012}
------------------------------------------------

HEK 293T cells were obtained from the Cell Bank of Chinese Academy of Sciences (<http://www.cellbank.org.cn>) and maintained in Dulbecco\'s Modified Eagle Medium (DMEM) with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (PS) at 37°C in a humidified incubator with 5% CO~2~. One day before transfection, cells were plated at 150,000 cells per well in 6‐well culture dish. The next day, cells were transfected with 2.5 μg of EGFP control plasmid DNA or DCTN1‐EGFP wild‐type (DCTN1‐WT) or mutant (c.626dupC and c.C3823T) plasmid DNA using Lipofectamine 3000 transfection reagent (Invitrogen). Forty‐eight hours later, the cells were split in radio immunoprecipitation assay (RIPA) buffer (Beyotime) to extract protein for western blot analysis. Cell lysates were diluted in 6X SDS‐PAGE Sample Loading Buffer (Beyotime) for protein denaturation. For cell lysates, equal volumes were run on 8% SDS polyacrylamide gels. Total DCNT1 levels were detected using the anti‐GFP antibody (1:2500, GFP‐1010, AVES). GAPDH primary antibody (1:1000, 2118‐14C10, Cell Signaling Technology) or Histone H3 primary antibody (1:2000, D1H2, Cell Signaling Technology) were used to ensure equal protein loading. Blots were then incubated with anti‐chicken and anti‐rabbit secondary HRP‐conjugated antibodies (1:5000, Beyotime) and bands were detected by enhanced chemiluminescence using Western Blot Enhancer reagents (Thermo Scientific).

Fibroblasts from Patient 1 and control individual were obtained from skin biopsies after informed consent. Fibroblasts were maintained at 37°C in a humidified incubator containing 5% CO2 in Dulbecco\'s modified Eagle\'s medium supplemented with 10% calf bovine serum and 0.1% gentamycin. Protein of fibroblast cell lysate was extracted and the expression level of DCTN1 was detected by western blotting with mouse anti‐p150 Glued (1:1000, 610473, BD Transduction Laboratories) or goat anti‐DCTN1 (1:1500, ab11806, Abcam).

Primary neuron culture {#acn350985-sec-0013}
----------------------

Primary cell culture of cortex neurons was performed as described.[13](#acn350985-bib-0013){ref-type="ref"} Briefly, cortex neurons were dissociated from P0 pups. The triturated cells (1 × 10^5^ cells per well) were grown on glass coverslips coated with 10 μmol/L poly‐lysine overnight in 24‐well dishes. Then the culture was grown in a medium of Neurobasal A media (Gibco) supplemented with B27 and 2 mmol/L glutamine for the indicated number of days. The cortex neurons were transfected with DCTN1‐WT/Mut plasmid at DIV7 using the calcium phosphate method.

Immunofluorescence {#acn350985-sec-0014}
------------------

HEK 293T cells and primary neuron transfected with the respective expression constructs were washed in PBS and fixed using 4% paraformaldehyde for immunofluorescence test. Cells were blocked with 10% normal donkey serum and 0.3% Triton X‐100 in PBS for 60 min, incubated with primary antibody (GFP‐1010, AVES; α‐Tubulin‐11H10, CST) in blocking solution at 4°C overnight and incubated with Alexa Fluor 488 or 594 secondary antibodies (1:1000, Life). DAPI (4′,6‐diami‐dino‐2‐phenylindole) (1:10,000, Life) was used for nucleic acid staining. Images were taken with a Zeiss 710 confocal microscope.

Data availability statement {#acn350985-sec-0015}
---------------------------

The original dataset used and analyzed for this study is available from the corresponding author on reasonable request.

Results {#acn350985-sec-0016}
=======

Clinical findings {#acn350985-sec-0017}
-----------------

Patient 1 (T3188) is a 23‐year‐old man with lifelong weakness of distal limbs, abnormal gait, and congenital foot malformation. He was born of full‐term spontaneous vaginal delivery with normal birth weight (3.1 kg). Bilateral clubfoot was observed at birth. He achieved sitting and standing at 10 months and 2 years old, respectively. At the age of three years, he learned to walk alone but was unstable, with falling every 5--6 steps. Orthotics surgeries were performed on feet twice at the age of 1 and 6 years, respectively. Hands are clumsy since childhood, especially for delicate manipulating. At the age of 16 years, the muscle twitching on both thighs appeared. Wearing the orthopedic shoes, he may walk slowly and vacillatingly. However, distal dominant limb weakness and muscle atrophy slowly progressed without any sensory disturbances. At the age of 23 years, he was 180 cm in height with body weight 52 kg, clear in speech and alert in recognition. Upon evaluation, tongue fasciculations was continuous when stuck out. He had normal strength in neck flexion and proximal limbs (5/5 rated on a scale of 0/5--5/5), but reduced strength of grip (4/5). Muscle tone in four limbs was normal. Fingers could not be straightened with limited interphalangeal joint extension, obvious interosseous, and thenar muscle atrophy (Fig. [1](#acn350985-fig-0001){ref-type="fig"}A and B) as well as postural tremor. Muscle atrophy below knee was eye‐catching. Foot deformity was composed of Achilles tendon contracture as well as toe varus (Fig. [1](#acn350985-fig-0001){ref-type="fig"}C and D). Tendon reflexes were brisk in four limbs. Patellar clonus was positive on the right side. The pathological plantar reflex examination was not completed due to unsatisfactory cooperation. Ptosis, nystagmus, dysarthria, dysphagia, ataxia, muscle pain, and dyspnea were not noticed. Mental psychological and cognitive tests were normal. He has been training in backstroke team for six years mainly depending on arm strength. The electrophysiologic showed nerve conduction velocity was normal. Compound muscle action potential (CMAP) was decreased in nervus peroneus communis (0.96 mV), median nerve (1.27 mV), and ulnar nerve (4.4 mV). The duration and amplitude of motor unit potential (MUP) and multiphase potentials were increased, without spontaneous activity, indicating extensive chronic neurogenic lesions. Figure [1](#acn350985-fig-0001){ref-type="fig"}E showed the X‐ray photography of distal extremities at the age of 23 years.

![Clinical, pathological, genetic, and functional characterizations. (A--D) Hands (A and B) and lower limbs (C and D) of Patient 1. (E) X‐ray photograph of lower limbs of Patient 1 showing bilateral talipes equinovarus. (F and G) Peripheral nerve pathology of the Patient 1 showed mild density decrease of large myelinated fibers by toluidine blue staining (F) and under electronic microscopy (G). (H) Sequence chromatograms of *DCTN1* gene of Patient 1's family. It displays one de novo insertion mutation of c.626dupC (arrow) in the proband. F = father, M = mother, P1 = patient 1. (I) Sequence chromatograms of *DCTN1* gene of Patient 2's family. It displays one de novo missense mutation of c.3823C\>T (arrow) in the proband. (J) Western blotting showed the expressions of DCTN1‐Mut (L210Afs\*90) were significantly lower than healthy control. Western blotting showed the DCTN1‐WT and R1275C with molecular weight of 150 kDa. DCTN1‐L210Afs\*90 with relative smaller molecular weight (∼55 kDa) was detected. (K) DCTN1‐WT/Mut‐EGFP transfected HEK 293T cells showing the presence of WT in cytoplasmic distribution colocalizing with α‐tubulin but L210Afs\*90 is expressed in nuclear and R1275C forms punctate aggregates. The scale bar represents 20 μm. (L) Immunofluorescence of DCTN1‐WT/Mut in primary mouse cortex neuron showing WT and R1275C is expressed in both body and axon, but L210Afs\*90 is only expressed in the body. The scale bar represents 20 μm. (M) Western blotting of separated whole cell/nuclear/cytoplasmic components showed the L210Afs\*90 is mainly expressed in nuclear. GAPDH and His‐3 are set as housekeeping proteins. C = cell, N = nuclear, P = cytoplasmic. (N--O) Western blotting showed a strong signal at \~150 kDa of skin fibroblasts from control samples. There was relative weak signal detected in the Patient 1's protein using either N‐terminus (N) or C‐terminus antibody (O). A signal at relative smaller molecular weight (\~55kDa) was detected in the patient but not in control using N‐ terminus antibody (N).](ACN3-7-200-g001){#acn350985-fig-0001}

Patient 2 (T3658) is a 46‐year‐old woman with progressively worsened weakness and muscle atrophy for 2 years. Initially, weakness affected the right lower limb, leading to occasional falls during walking. Gradually, both lower limbs and hands got involved with interosseous muscle atrophy. Meanwhile, the sensation of muscle twitching developed all over the body. She became incapable of looking after herself and walking alone within only one year, with obvious weight loss, swallowing difficulty, and breath shortness. The parameters of postnatal and adolescent development did not provide any clue of growth abnormality. However, she had constipation for more than 30 years. Upon physical examination, she presented reduced fluency of speech and tongue fasciculations. She had reduced strength in neck flexion (1/5), distal upper limbs (3/5), and lower limbs (4/5), but normal strength in proximal upper limbs (5/5). Atrophy of interosseous and thenar muscles. Muscle tone in four limbs was normal. Tendon reflexes were brisk in four limbs with persistent patellar clonus and ankle clonus. The pathological plantar reflex was negative. Mental psychological and cognitive tests were in normal range. The electrophysiologic examination showed decreased motor nerve conduction velocity and CMAP amplitude, with fibrillation and positive sharp waves, widened MUP upon light contraction, with or without multiphase potential.

Neuropathological findings {#acn350985-sec-0018}
--------------------------

Sural nerve biopsy was performed on Patient 1, without significantly morphological changes by HE, MGT, Congo Red staining. Myelinated fibers of large diameter are slightly decreased in density by toluidine blue staining (Fig. [1](#acn350985-fig-0001){ref-type="fig"}F) or under electronic microscopy (Fig. [1](#acn350985-fig-0001){ref-type="fig"}G).

Genetic findings {#acn350985-sec-0019}
----------------

Patient 1 was identified with a de novo frameshift heterozygous variant c.626dupC (p.L210Afs\*90) in *DCTN1* gene (Fig. [1](#acn350985-fig-0001){ref-type="fig"}H). Patient 2 was identified with a de novo missense heterozygous variant c.C3823T (p.R1275C) in the same gene (Fig. [1](#acn350985-fig-0001){ref-type="fig"}I). Both variants were not identified in the patients' parents, 300 healthy controls, dbSNP (<http://www.ncbi.nlm.nih.gov/snp>), 1000 Genome Project (<http://browser.1000genomes.org>), NHLBI Exome Sequencing Project (ESP) Exome Variant Server (<http://evs.gs.washington.edu/EVS>) or Exome Aggregation Consortium (ExAC). p.L210Afs\*90 was predicted to be disease causing by Mutationtaster (probability score 1.000). p.R1275C was predicted to be probably damaging by PolyPhen2 (probability score 0.997, sensitivity: 0.41, specificity: 0.98), damaging by SIFT (SIFT score: 0.000), and disease causing by Mutationtaster (probability score 0.999).

Mutant protein detection {#acn350985-sec-0020}
------------------------

The expression of DCTN1‐WT/Mut was examined by western blotting after transfecting HEK 293T cells with DCTN1 constructs, showing the p.L210Afs\*90 with smaller molecular weight than WT (Fig. [1](#acn350985-fig-0001){ref-type="fig"}J). In immunofluorescence staining (Fig. [1](#acn350985-fig-0001){ref-type="fig"}K), the p.L210Afs\*90 completely overlapped with DAPI‐stained nucleus in comparison with the cytoplasmic distribution of WT. The cytoplasmic colocalization of DCTN1‐WT and α‐tubulin was confirmed. However, R1275C tended to form punctate aggregates, partially losing colocalization with α‐tubulin. Furthermore, to figure out how the mutant protein acted in primary neuron, we transfected DCTN1‐WT/Mut into mouse cortex neuron. Both WT and R1275C distributed throughout the neuron both body and axon (Fig. [1](#acn350985-fig-0001){ref-type="fig"}L). p.L210Afs\*90 could not reach out to the axon and mainly expressed in the body (Fig. [1](#acn350985-fig-0001){ref-type="fig"}L). In western blotting, p.L210Afs\*90 was almost exclusively expressed in the separated nucleus lysate (Fig. [1](#acn350985-fig-0001){ref-type="fig"}M). We further tested the expression of DCTN1 in Patient 1's skin fibroblasts. A truncated smaller DCTN1 was tested at around 55kD using anti‐DCTN1 N‐ter antibody (Fig. [1](#acn350985-fig-0001){ref-type="fig"}N). Using anti‐DCTN1 C‐ter antibody, we can see the expression of DCTN1 of whole length in Patient 1 was half of healthy control via three repeated tests (Fig. [1](#acn350985-fig-0001){ref-type="fig"}O).

Discussion {#acn350985-sec-0021}
==========

We described two sporadic patients with motor neuron disease due to de novo mutations in *DCTN1*, c.626dupC, and c.C3823T, respectively. Patient 2 manifested with typical features of ALS. However, Patient 1 with distal motor neuropathy had an extremely early age of onset as well as congenital foot deformity, in comparison with all other DCTN1‐related cases reported before. Interestingly, *DCNT1* mutation can also lead to Perry syndrome, which is characterized by rapidly progressive parkinsonism accompanied by depression/apathy, unintentional weight loss and respiratory failure.[4](#acn350985-bib-0004){ref-type="ref"}, [8](#acn350985-bib-0008){ref-type="ref"}, [14](#acn350985-bib-0014){ref-type="ref"} Patients usually show levodopa‐resistant/responsive resting tremor, rigidity, bradykinesia, postural instability and autonomic dysfunction, and reminiscent of Parkinson's disease. Therefore, Perry syndrome can be easily misdiagnosed as Parkinson's disease, especially during early stage. The major death cause is central hypoventilation or pneumonia.[8](#acn350985-bib-0008){ref-type="ref"}, [15](#acn350985-bib-0015){ref-type="ref"}, [16](#acn350985-bib-0016){ref-type="ref"}, [17](#acn350985-bib-0017){ref-type="ref"}, [18](#acn350985-bib-0018){ref-type="ref"} The clinical characterizations of DCNT1‐related spectrum are summarized in Table [1](#acn350985-tbl-0001){ref-type="table"}.

###### 

Clinical characterizations of *DCTN1*‐related spectrum.

  Phenotype                 dHMN                                            ALS                                                                                                                     Perry syndrome
  ------------------------- ----------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------
  Onset                     Early adulthood or earlier                      48--64 yrs                                                                                                              35--70 yrs
  Disease duration          Slow progression                                4--9 yrs                                                                                                                ≤5 yrs
  Initial symptoms          Hand weakness                                   Hand and lower limb weakness                                                                                            Depression/apathy, parkinsonism, weight loss, central hypoventilation
  Cardinal symptoms         Face, distal limb weakness and muscle atrophy   Progressive limb weakness and muscle atrophy, increased muscle tone, tendon hyperreflexia, positive pathological sign   Parkinsonism, depression/apathy, respiratory symptoms, weight loss
  Bulbar symptoms           Vocal cord paralysis, shortness of breath       Vocal cord spasm, difficulty speaking, difficulty swallowing                                                            Dysphasia, difficulty swallowing
  Other clinical features   Foot deformity                                  Constipation, severe unintentional weight loss, frontotemporal dementia                                                 Cognitive impairment, sleep disturbances
  Cause of death            NA                                              Respiratory failure                                                                                                     Respiratory failure/pneumonia
  Motor neuron involved     Distal motor neuropathy                         Both upper and lower motor neuron                                                                                       Upper motor neuron

dHMN = distal hereditary motor neuropathy, ALS = amyotrophic lateral sclerosis, yrs = years, NA = not available.

John Wiley & Sons, Ltd

The *DCTN1* gene encodes Dynactin subunit 1, the biggest subunit among all 10 subunits of Dynactin complex. P150^Glued^ is encoded by full‐length *DCTN1* gene, weights around 150 kD and contains the N‐terminal cytoskeleton‐associated protein glycine‐rich (CAP‐Gly) domain, followed by two coiled‐coil domains (CC1 and CC2).[1](#acn350985-bib-0001){ref-type="ref"} The CAP‐Gly domain (aa 48--90) has a ^(67)^GKNDG^(71)^ motif, which is evolutionarily conserved and plays a critical role in microtubule binding.[1](#acn350985-bib-0001){ref-type="ref"}, [19](#acn350985-bib-0019){ref-type="ref"}, [20](#acn350985-bib-0020){ref-type="ref"} Dynactin 1 is essential in enriching dynactin at neurite tips through the end‐binding proteins (EB1 and EB3), which are both microtubule‐binding molecular.[21](#acn350985-bib-0021){ref-type="ref"} Dynactin accumulation enhances recruitment and sustained engagement of dynein.[22](#acn350985-bib-0022){ref-type="ref"}, [23](#acn350985-bib-0023){ref-type="ref"} It is also required for the dynein‐driven retrograde flux of organelles and vesicles along microtubules from distal axon.[2](#acn350985-bib-0002){ref-type="ref"}, [24](#acn350985-bib-0024){ref-type="ref"}, [25](#acn350985-bib-0025){ref-type="ref"}

So far, a total of 29 mutations in *DCTN1* have been associated with diseases, including 26 missense, 1 frameshift, and 2 splicing variants (Fig. [2](#acn350985-fig-0002){ref-type="fig"}). Interestingly, all the Perry syndrome‐related mutations map to CAP‐Gly domain (9/9, Fig. [2](#acn350985-fig-0002){ref-type="fig"}, brown), among which G71A, G71R, G71E, T72P, and Q74P affect the EB1 interaction and the stability of CAP‐Gly domain.[26](#acn350985-bib-0026){ref-type="ref"} Moreover, most of the ALS‐related mutations are more likely to locate on C‐ter half (10/14, Fig. [2](#acn350985-fig-0002){ref-type="fig"}, green). Among these, several have been confirmed to result in lower DCTN1 protein expression.[27](#acn350985-bib-0027){ref-type="ref"}, [28](#acn350985-bib-0028){ref-type="ref"} c.C3823T (p.R1275C) found in Patient 2 with ALS, lies within the domain (aa 911--1278) interacting with Hermansky‐Pudlak syndrome 6 protein (HPS6).[29](#acn350985-bib-0029){ref-type="ref"} The R1275C appearing as cytoplasmic aggregates, completely lost colocalization with microtubules. In the cytoplasm, organelle transport from cell periphery to perinuclear site is dependent on the interaction between microtubule networks and dynein/dynactin complex, such as the centripetal movement of endosomes and autophagosomes.[1](#acn350985-bib-0001){ref-type="ref"}

![The schematic diagram of DCTN1 structure with mutations. Full length of DCNT1 (NM_004082) in brown consists of 1278 amino acids. Mutations identified with dHMN, ALS, and Perry syndrome are in red, green, and brown, respectively. Mutations firstly identified in this paper are in bold font, c.626dupC (p.L210Afs\*90) and c.C3823T (p.R1275C).](ACN3-7-200-g002){#acn350985-fig-0002}

There are another six mutations identified in patients with lower motor neuron disease (Fig. [2](#acn350985-fig-0002){ref-type="fig"}, red), among which, DCTN1‐G59S has been confirmed with weakened affinity with microtube.[6](#acn350985-bib-0006){ref-type="ref"} To be noted, DCTN1‐related HMN reported previously are all adult‐onset. Nevertheless, c.626dupC (p.L210Afs\*90), the only frameshift mutation, is identified in our patient with congenital bilateral clubfoot, delay in motor milestones, and neonatal‐onset lower motor neuron disease. p.L210Afs\*90 is located in front of the first coiled‐coil domain (CC1), responsible for binding the dynein intermediate chain.[30](#acn350985-bib-0030){ref-type="ref"}, [31](#acn350985-bib-0031){ref-type="ref"} The frameshift results in changes of a series of amino acids downstream and introduces a premature stop codon, leading to 979 missing amino acids (76.6% of the whole length). At the N‐ter of DCTN1, aa ^(148)^RRPKP^(152)^ is a nuclear localization signal (NLS) tagging the protein to be imported into cell nucleus. Besides, aa ^(227)^LEEKLETLRL^(236)^ is a nuclear export signal (NES) targeting the protein to be exported from cell nucleus to the cytoplasm. The frameshift occurred between NLS and NES, leading to NLS remained but NES missed. Consistently, we find the truncated Dynactin 1 protein trapped into the nuclear thus losing right cytoplasmic localization and interaction with microtubule. In Western blotting, the whole‐length band from Patient 1 is weaker than the control's, and the band of truncated mutant (about 55kDa) is even weaker, indicating the mutant protein might be recognized by protein degradation pathway. Consequently, c.626dupC (p.L210Afs\*90) is mostly likely to cause haploinsufficiency due to frame‐shift caused loss‐of‐function.[32](#acn350985-bib-0032){ref-type="ref"} During mitosis, microtubules are required to control the rearrangements of the nuclear membranes.[33](#acn350985-bib-0033){ref-type="ref"} Especially in G2/M transition, nuclear membrane surrounding chromosomes in interphase should be replaced by cytoplasmic spindle microtubules.[34](#acn350985-bib-0034){ref-type="ref"}, [35](#acn350985-bib-0035){ref-type="ref"} p150^Glue^, localizing in the nuclear envelope during prophase, plays an essential role in nuclear envelope breakdown (NEBD).[36](#acn350985-bib-0036){ref-type="ref"} Dynein/dynactin is required for the mitosis as germline deletion of p150^Glued^ causes early embryonic lethality and apoptosis in p150^Glued^ knockout mice.[37](#acn350985-bib-0037){ref-type="ref"} The depletion of p150^Glued^ induces severe cell‐cycle block before mitosis, due to the lack of NEBD.[36](#acn350985-bib-0036){ref-type="ref"} Similar phenotypes have also been observed in another cell‐cycle regulation gene, *VRK1* (vaccinia‐related kinase 1), including dHMN, ALS, and spinal muscular atrophy (SMA).[38](#acn350985-bib-0038){ref-type="ref"}, [39](#acn350985-bib-0039){ref-type="ref"}

P150^Glued^ is essential in maintaining microtubule stability by acting as an anticatastrophe factor in neuronal cultures.[40](#acn350985-bib-0040){ref-type="ref"} However, we did not observe any substantial loss of axons in peripheral nerve biopsy for Patient 1. Similar findings were convinced in p150^Glued^ cKO mice, where the increased acetylation of α‐tubulin may serve as a compensatory mechanism to maintain the microtubule integrity in the absence of p150Glued.[41](#acn350985-bib-0041){ref-type="ref"} During fetal development, limbs may fail to grow properly due to congenital or acquired factors.[42](#acn350985-bib-0042){ref-type="ref"}, [43](#acn350985-bib-0043){ref-type="ref"} However, Patient 1's mother was never exposed to poisonous or pernicious environment during pregnancy. In addition, the genetic study does not reveal mutations in known genes associated with congenital club foot.[44](#acn350985-bib-0044){ref-type="ref"} As the relationship between limb and nervous system development discussed before,[45](#acn350985-bib-0045){ref-type="ref"}, [46](#acn350985-bib-0046){ref-type="ref"} patients with hereditary neuropathies may present with early or congenital foot deformities and variable delay in motor milestones due to several genes, such as *FGD4*, *PRX*, *MTMR2*, *SBF2*, *SH3TC2*, *GDAP1* mutations, and Charcot--Marie--Tooth type 1A (CMT1A) duplication.[47](#acn350985-bib-0047){ref-type="ref"} In this study, the early‐onset dHMN plus congenital foot deformity is probably related with the large fragment deletion of DCTN1 as well as lose of appropriate cytoplasmic localization.

Both ALS and Perry syndrome are rapidly progressing and even leading to death within 4--9 years, whereas the progress of dHMN is relatively slow.[4](#acn350985-bib-0004){ref-type="ref"} Although the genotype--phenotype correlation can be partially summarized (Fig. [2](#acn350985-fig-0002){ref-type="fig"}), the specific mechanisms by which different mutations lead to different phenotypes remain unclear.

Conclusion {#acn350985-sec-0022}
==========

This work reported new phenotype of *DCTN1*‐related spectrum and identified two novel *DCTN1* mutations causing different phenotypes, early‐onset dHMN plus congenital foot malformation and ALS. The mutations lead to abnormal Dynactin 1 distribution, losing the colocalization with microtubule. This study provides the initial evidence that truncated Dynactin 1 trapped within nuclear and can be related with lower limb development abnormality and an extremely early‐onset form of dHMN. Thus, we suggest that *DCTN1*‐related spectrum is still expanding.
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